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The effect of vitamin D, magnesium and zinc 
supplements on interferon signaling pathways 
and their relationship to control SARS‑CoV‑2 
infection
Mohsen Nabi‑Afjadi1, Hadis Karami2, Kaveh Goudarzi3, Iraj Alipourfard4 and Elham Bahreini5*  
Abstract 
The concern of today’s communities is to find a way to prevent or treat COVID‑19 and reduce its symptoms in the 
patients. However, the genetic mutations and more resistant strains of severe acute respiratory syndrome coronavirus 
2 (SARS‑CoV‑2) emerge; the designed vaccines and adjuvant therapies would potentially control the symptoms and 
severity of COVID‑19. The most important complication of this viral infection is acute respiratory distress syndrome, 
which occurs due to the infiltration of leukocytes into the alveoli and the raised cytokine storm. Interferons, as a 
cytokine family in the host, play an important role in the immune‑related antiviral defense and have been considered 
in the treatment protocols of COVID‑19. In addition, it has been indicated that some nutrients, including vitamin D, 
magnesium and zinc are essential in the modulation of the immune system and interferon (IFN) signaling pathway. 
Several recent studies have investigated the treatment effect of vitamin D on COVID‑19 and reported the association 
between optimal levels of this vitamin and reduced disease risk. In the present study, the synergistic action of vitamin 
D, magnesium and zinc in IFN signaling is discussed as a treatment option for COVID‑19 involvement.
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Introduction
Currently, much of the world’s attention is focused on 
finding a way to prevent or treat COVID-19 disease or 
reduce its symptoms in patients. Many researchers have 
offered various solutions and recommendations in this 
regard, but they need to be proven. Severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2) belongs to 
the positive-strand RNA viruses family with a crown-
like appearance. The viral genome contains S, E, M, and 
N genes that encode structural proteins and the ORF 
region, which expresses non-structural proteins such as 
papain-like protease, 3-chymotrypsin-like protease and 
RNA-dependent RNA polymerase [1]. The virus spreads 
by the scattered droplets through coughing, sneezing, or 
exhaling from a person’s mouth and nose with COVID-
19. The virus enters the nasal system by inhalation and 
begins to multiply [2].
Among the structural proteins, glycoprotein S or spike 
protein, which abundantly covers the surface of SARS-
CoV-2, binds to the host cell receptor of angiotensin-con-
verting enzyme 2 (ACE2). It is the major contributor to 
virus entry into the cell and causing infection [3, 4]. Nota-
bly, SARS-CoV-2 does not use other coronavirus recep-
tors such as aminopeptidase N and dipeptidyl peptidase. 
By binding S protein to the receptor, transmembrane 
protease/serine subfamily member 2 (TMPRSS2), a 
known human protease located primarily in the airways 
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and alveolar cell membranes, activates and facilitates 
virus entry into the cell by cleaving protein S and ACE2. 
Furin is another enzyme found in the host cell which has 
a crucial role in the entrance of the virus (Fig. 1) [5, 6]. 
In addition to TMPRSS2 and furin, other S-activating 
proteases including cathepsin L, trypsin, elastase, ther-
molysin, factor Xa, and plasmin may also have a role as 
SARS-CoV-2 entry cofactors. In the lack of prior ACE2 
binding, these proteases can excessively proteolyze S 
proteins and inactivate virus infection [4, 7]. Thus, SARS 
causes more severe clinical signs and symptoms in tissues 
with high ACE2 densities on the cell surface, especially 
vascular endothelial cells of the lung and extrapulmonary 
tissues such as the gastrointestinal tract, kidneys, liver, 
testes, and heart [4].
The natural role of ACE2 is to reduce the concentra-
tion of tissue angiotensin II (Ang II) by its conversion 
to Ang-(1-7), which acts as an anti-inflammatory agent. 
The major pathologic aspect of COVID-19 is the eleva-
tion of Ang II levels directly related to viral load and lung 
damage. Ang II promotes the expression and activation 
of inflammatory cytokines such as interleukin (IL)-6 and 
thrombin formation and inhibition of fibrinolysis. SARS-
CoV-2 also has a strong affinity to bind to porphyrins 
and reduces the level of functional intracellular hemo-
proteins [4, 8]. Dysfunction of porphyrins and hemo-
proteins leads to the release of free iron, especially from 
dying cells, which results in a severe systemic inflam-
matory response, tissue damage and a pro-thrombotic 
state [8]. In this situation, the alveolar epithelial barrier 
is destructed, the lung defense mechanism is weakened 
and the permeability of the pulmonary arteries increases. 
It leads to recruitment and influx of activated neutro-
phils and macrophages, pulmonary edema, and eventu-
ally acute respiratory distress syndrome (ARDS). The 
alveoli infiltrated with activated neutrophils, cytokines/
chemokines, and protein-rich secretions would not 
ventilate enough to provide oxygen. Therefore, some fac-
tors by which to strengthen the immune system may help 
potentialy control COVID-19 and related respiratoty 
symptoms [8].
At present, there is no assured treatment that can 
directly target SARSE-CoV2. Moreover, variable genetic 
mutations and the emergence of more resistant strains of 
the virus also calls into question the efficacy of designed 
vaccines. However, several adjuvant therapies can be 
used to control the symptoms and severity of COVID-
19 until discovering an anti- SARSE-CoV2 drug in the 
future. Some vitamins, minerals and herbal derivatives 
are efficient supplementals in maintaining the func-
tion of the immune system and have synergistic effects 
next to medical therapies [9, 10]. Previous studies have 
shown an association between some vitamin and mineral 
deficiencies and immunodeficiency against respiratory 
pathogens, as well as more extended recovery periods 
from disease. For example, it is evidenced that C, D and 
E vitamins and some minerals like zinc, selenium, and 
omega-3 fatty acids enrich the immune system to prevent 
and treat infectious diseases. It has been claimed that 
concomitant use of these compounds with azithromycin 
may be more effective in the rapid recovery of a patient 
infected by SARS-CoV-2 [11]. Interferons (IFNs) are 
internal antiviral agents of which, in combination with 
such supplements, may have synergistic treatment effects 
on the COVID-19 disease [12, 13]. Hereby, this article 
aims to discuss the anti-inflammatory effects of IFNs on 
SARS-CoV-2 infection and rather complementary effects 
of vitamin D and minerals.
The common pattern of virus‑induced 
hyperinflammation of respiratory viruses
The twenty-first century has a global impact on health due 
to the spread of a variety of respiratory viruses following 
successive mutations, which cause acute inflammation 
with high mortality rates. Overproduction of inflamma-
tory cytokines in various SARS-CoV-2 viral infections 
indicates a severe immunopathological process [14, 15]. 
Due to the manifestations of influenza infection, includ-
ing high levels of cytokines and chemokines such as IL-6, 
IL-1β, TNF-α, IL-10, and elevated serum ferritin levels, a 
similar association was shown between infection caused 
by the SARS-CoV-2 viral epidemic and seasonal human 
influenza viruses [16]. In influenza and COVID-19 infec-
tions, cytokine storm is closely related to coagulopathy 
and disseminated intravascular coagulation [17]. Both 
influenza and SARS-CoV viruses induce NLRP3 (NLR 
family pyrin domain containing 3) inflammasome activa-
tion [18], associated with pyroptosis—a highly inflamma-
tory form of lytic programmed cell death- upon infection 
with intracellular pathogens. Lymphocytopenia, as well 
Fig. 1 The role of spike protein and ACE2 receptor in the 
internalization of SARCE‑CoV2. The transmembrane proteases of 
TMPRSS2 and FURIN 2 facilitate viral infection
Page 3 of 10Nabi‑Afjadi et al. Clin Mol Allergy           (2021) 19:21  
as reduced polyfunctionality and cytotoxicity of T-cells 
and NK cells due to the continuous expression of inhibi-
tory markers such as programmed cell death protein-1 
(PD-1) and T-cell immunoglobulin domain and mucin 
domain protein-3 (TIM-3), are characteristics of both 
influenza infection and COVID-19 [19, 20]. The reverse 
correlation between PD-1 and TIM-3 protein markers 
with total counts of CD8- and CD4-T cells, but not neu-
trophil counts, makes both parameters a good predictive 
criterion for COVID-19 progression and severity [20]. 
TIM-3 participates in cytokine storm during COVID-19 
by activating infected macrophages and negatively regu-
lating the Th1 immune response in the cytokine storm, 
and subsequently causes overstimulation of the innate 
immune system [20]. In addition to TIM-3, the activation 
of the PD-1/PD-L1 pathway in severe H1N1 influenza 
A infection has been demonstrated in tissue samples of 
the lower respiratory tract in pediatric patients and their 
dendritic and T cells as well [21, 22]. PD-L1 expression 
levels are inversely related to the number of CD8 + T cells 
in these patients, and inhibition of this pathway improves 
the number and function of CD8 + T cells [23]. Rutigli-
ano et al. showed that decreased CD8 + T cells activity in 
influenza A virus infection in mice was associated with 
increased PD-1 expression [24]. They found that blocking 
PD-L1 in vivo can reduce the virus titer and increases the 
number of CD8 + T cells but not their activity. Another 
study reported that the recovery period from influenza 
infection in PD-1 -/- mice are much longer than the wild 
ones [25]. These findings show the dual role of the PD-1 / 
PD-L1 pathway, which negatively regulates CD8 + T cells 
and slows virus clearance.
As mentioned, severe cases of influenza and COVID-
19 share a similar immune response, including a reduced 
number of circulating CD8 + and CD4 + T cells and 
increased amounts of proinflammatory cytokines [26, 
27]. The lower number of acute immune cells in the 
acute phase of severe disease may be due to the migra-
tion of these cells to the respiratory tract; in fact, there 
may be no reduction in the production of immune cells. 
Autopsy of patients with COVID-19 showed diffuse infil-
tration of lymphocytes, especially CD8 + T cells into the 
lungs, along with focal infiltration into the liver, kidney, 
pancreas, intestine, adrenal, and pericardium. Such lym-
phocyte migrations and following cytokine storm could 
promote apoptosis or necrosis of T cells and conse-
quently reduce their number in blood circulation [28].
Interventions of IFNs and their agonists 
with SARS‑CoV‑2 infection
The cytokine storm, an abrupt rise of serum inflamma-
tory cytokines and chemokines in SARS-CoV-2, influ-
enza, and MERS-CoV infections trigger a severe systemic 
inflammatory response that must be controlled to limit 
tissue damage [16]. Interferon cytokines as the first 
line of defense against viral infections are secreted by 
immune-activated cells and activate natural killer cells 
(NK) and macrophages. Type I IFNs includes IFN-α and 
IFN-β, while IFN-γ and IFN-λ belong to type II and type 
III IFNs, respectively [29]. IFNs bind to their receptors on 
the cell surface and activate several genes involved in the 
antiviral process by inducing the Janus-activated kinase 
(JAK)/signal transducer and activator of transcription 
(STAT) signaling pathway. In this signaling pathway, the 
activated IFN-receptor induces Janus kinase 1 (JAK1) 
and Tyrosine kinase 2 (TYK2), which then phosphorylate 
STAT1and STAT2. These phosphorylated factors enter 
the nucleus and are assembled with interferon-regulatory 
factor 9 (IRF9). The activated IRF9 stimulates interferon-
stimulated gene factor 3 (ISGF3) and subsequently the 
transcription of interferon-stimulated genes (ISGs). ISGs 
are important contributors to virus-induced immune 
responses [30, 31].
Anti-inflammatory effects are another role of IFNs that 
are associated with the suppression of pro-inflammatory 
cytokines such as IL-1, IL-18 and IL-12 and the induc-
tion of anti-inflammatory cytokine IL 10. In SARS-CoV-2 
infection, there are abnormally low levels of antivi-
ral cytokines, especially type I IFNs [17, 18]. Therefore, 
IFNs are considered an important target to control 
cytokine storms and inflammation within the treatment 
of COVID-19. A well-documented strategy of coronavi-
rus reported as an elimination of host interferon’s defense 
system through interference to their production and sign-
aling pathway. For example, a reduction in IFN-γ expres-
sion has been observed in  CD4+ T cells of patients with 
COVID-19 associated with disease severity [19]. IL-6 
can also differentiate Th2 cells from Th0 by activating 
the STAT3 signaling pathway and eventually producing 
Th2 cytokines such as IL-13 and IL-4, as well as suppress 
cytokine signaling 1 (SOCS-1). SOCS-1, as an inhibitory 
molecule through its effects on STAT1 phosphorylation, 
can disrupt the production of IFN-γ and IL-2 and lead to 
a decrease in the level of these cytokines by Th1 cells [32]. 
On the other hand, increasing IL-6 and finally SOCS-1 by 
interfering with STAT4 phosphorylation has an inhibi-
tory effect on IFN-γ and IFN-II production. These IFNs 
are involved in the cytolysis of infected cells by stimulat-
ing and activating killer cells, including NK and CD8 + -T 
cells. One of the main mechanisms in the removal of 
virus-infected cells in the progression of apoptotic path-
ways and their associated molecules by pro-apoptotic 
molecules such as granzyme B, which are produced and 
secreted by killer cells [33]. According to the described 
mechanism, the survival of infected cells can be affected 
by IL-6 because this multifunctional cytokine can induce 
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anti-apoptotic molecules by stimulating Th17 differentia-
tion and IL-17 production [33]. Another chosen mecha-
nism by the virus for the development is the cooperation 
of IL-6 and IFN-I. These cytokines increase the survival 
of the infected cell by increasing inhibitory molecules 
such as PD-L1 (CD274) on the surface of the infected 
cell. The binding of PDL-1 to PD-1 (CD279) on CD8 + -T 
cells prevents apoptosis induced by these cells [33, 34].
Coronaviruses also avoid interactions with pattern-
recognition proteins (PRPs) responsible for inducing pro-
inflammatory reactions and antiviral responses mediated 
by IFN [20]. These mechanisms ultimately interfere with 
the production of IFNs and cause a delayed antiviral 
response mediated by IFNs. Some in  vitro studies have 
shown that IFN- therapies can inhibit viral replication 
and the combination of IFNs has a synergistic effect in 
this regard [35]. Thus, IFN- therapy is an accepted treat-
ment strategy to induce antiviral immune responses. 
However, IFN administration in the early stages of infec-
tion seems to affect effectively, leading to devastating 
responses in severe or later stages of the disease [36]. 
Although antibiotics are known as antibacterial agents, 
some also have antiviral effects, such as Macrolides. 
Macrolides composed of a large lactone ring bind to 
the 50S subunit of the bacterial ribosome and inter-
fere with protein synthesis [37]. There are some indica-
tions of macrolides to relieve viral respiratory infections 
[21]. The antiviral activity is attributed to their bind-
ing to IFN-receptor and inducing STAT1/2, IRF7, IRF9, 
and production of ISGF3 as well [22]. Clarithromycin 
and Leucomycin are the examples of Macrolides, used 
against the influenza virus to increase IFN-α production 
[23, 38]. Azithromycin is another macrolide that inhibits 
rhinoviruses via potentiating IFN-I signaling. It activates 
IκB-kinase (IKK), IKK-ι/ε, and TANK-binding kinase 1 
(TBK-1) signaling pathway, which stimulates the IRF fac-
tor, and IL-28 and IL-29 receptors [39, 40]. Azithromycin 
can induce the gene expression of IFN-β and IFNλ1, toll-
like receptor 3 (TLR3), melanoma differentiation-associ-
ated protein 5 (MDA5), RIG-I-like helicase, and retinoic 
inducible gene I (RIG-I) in bronchial epithelial cells [40, 
41]. The aforementioned agents act as antiviral pro-
teins in rder to reduce the viral load. Azithromycin also 
improves the cell sensitivity to viral infections through 
upregulation of pathogen recognition receptors (PRRs) 
of IFIH1, DDX58, and ISGs including IFITM3, MX1, and 
RASD2 [42, 43]. In addition to ACE2, CD147 is another 
binding receptor, that internalizes SARS-CoV-2 virus. 
Azithromycin may interfere with CD147 and the virus 
interaction process.
Ribavirin (Virazole), a guanosine analog, is another 
drug introduced by Witkowski et al. and originally used 
only to treat severe respiratory syncytial virus (RSV) 
infection in children [44]. It has a wide range of functions 
against RNA and DNA viruses, including infection with 
Lhasa fever virus, influenza A and B, and other viruses. 
It is also effective in combination with IFN-α in the treat-
ment of chronic hepatitis C infections [45, 46]. It com-
bines with viral RNA and, in addition to inhibiting the 
normal viral replication, causes mutations in its genome. 
It also inhibits RNA-dependent RNA polymerase activ-
ity. Following their bioinformatics studies, it has been 
claimed that the drug could bind to the active site of the 
enzyme and, by inhibiting it, could be a potent inhibitor 
for SARS-CoV-2 infection [47, 48].
Studies have indicated that some nutrients, including 
vitamin D, magnesium and zinc, play an essential role 
in the immune system and modulate the IFN signaling 
pathway. Adequate amounts of such micronutrients are 
crucial to ensure the proper functioning of the immune 
system. Vitamin D can control the production of proin-
flammatory cytokines and the cytokine storm observed 
in COVID-19 through affecting the nuclear factor-kB and 
other related pathways. Magnesium is a critical cofactor 
in the synthesis and activation of vitamin D [49]. Zinc is 
also important for the development of immune and other 
cells, so its deficiency leads to defects in humoral and cel-
lular immunity [50].
Potential role of activation of the vitamin D 
in acute respiratory distress syndrome (ARDS)
Vitamin D (VitD), as one of the oldest evolutionary 
hormones with a known role in the absorption of cal-
cium from the intestine, plays a role in regulating the 
immune system [51]. VitD receptor (VDR) is detected in 
all immune cells especially monocytes and macrophages 
and regulates their activity. it can potentially prevent a 
cytokine storm by reducing the expression of pro-inflam-
matory cytokines. Studies have shown a correlation 
between VitD deficiency and an increased risk of upper 
respiratory tract infection. A meta-analysis in 2019, using 
approximately 10,000 individual participant data from 25 
RCTs, concluded that vitamin D supplementation could 
reduce the risk of upper respiratory infections by 19%. 
The idea comes to the question is whether this conclu-
sion also applies to coronavirus infections [52].
As shown in Fig.  2, the signaling pathway activated 
through VitD complexed with its receptor (VDR) reduces 
cytokine and chemokine storm, modulates neutrophil 
activity, regulates the renin-angiotensin system (RAS), 
maintains pulmonary epithelial barrier integrity, and 
stimulates epithelial repair [53]. Animal studies and 
in vitro models have detected high levels of VDR in the 
alveolar type II cells (ACII) of the lung. They have shown 
that VitD acts like an endocrine system by increas-
ing the production and secretion of cytokines such as 
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IL-1β, IL-6, IL-12, IL-18, IL-33, IFN-α, IFN-γ, TNF-α, 
and chemokines such as CCL2, CCL3, CCL5, CXCL8, 
CXCL9, CXCL10 in acute respiratory syndrome [54, 55]. 
For example, following LPS treatment, VDR-knockout 
mice had more severe ARDS than wild-type mice. Xu 
et al., in their study on the mechanism of VitD effect on 
acute lung injury (ALI) induced by lipopolysaccharide 
(LPS) reported that VitD may attenuate LPS-induced ALI 
by modulating the expression of the RAS components, 
including ACE, ACE2, renin and Ang II. Li et  al., sug-
gested that VitD is a negative endocrine regulator of the 
RAS and inhibits renin biosynthesis [56]. Ishii showed 
that inhibition of renin receptors reduces inflamma-
tory symptoms, including interstitial edema, neutrophil 
count, hemorrhage, and the amount of pro-renin in the 
lung tissues of the study model [57]. Takano et  al. sug-
gested that the inhibitory effects of VitD on neutrophil 
recruitment in the hamster model of ALI could be due 
to its suppressive effect on the interleukin-8 (IL-8) gene 
involved in the pathogenesis of ALI [58].
Some genes regulated by VitD are key genes in the 
immune system’s response to many bacterial and viral 
infections [59]. Cathelicidin antimicrobial peptides 
(CAMP) of LL-37 and FALL-39 are antimicrobial mol-
ecules that are primarily synthesized and stored in the 
lysosomes of polymorphonuclear cells, and macrophages 
after activation by viruses, bacteria, parasites, fungi. VitD 
also stimulates the transcription of cathelicidins [60, 61]. 
The activated VDR by VitD acts as a transcription factor 
that influences the transcription of several genes includ-
ing the hCAP18 gene that encodes cathelicidin. Following 
cleavage by proteinase 3, the peptide precursor CAP-18 
(18 kDa) is processed into active forms LL-37 and FALL-
39 [62, 63].
The mechanism of action of cathelicidins is that, fol-
lowing the phagocytosis of the invasive agent and the 
attachment of the phagosomes to the lysosomes, the 
cathelicidins lyse it by damaging and perforating the 
membrane of the invasive agent cell, and providing the 
conditions for its complete destruction through lysoso-
mal degrading enzymes. Cathelicidins are also able to 
destroy the cover of enveloped viruses such as those of 
the Coronavirus family [64]. Thus, vitamin D can help 
regulate the immune system response and clear the 
SARS-CoV-2 virus by producing LL37. Remarkably, 
exposure to fine particulate air pollution, dust, and 
Fig. 2 a recruitment of activated neutrophils into the inflamed interstitium and alveolar space by cytokines and chemokines secreted from infected 
epithelial and endothelial cells and activated alveolar macrophages; b cytokines and chemokines secreted by activated leukocytes cause cytokine 
and chemokine storms that are involved in the pathogenesis of ARDS; C dysregulation in homeostasis resulted in intra‑alveolar or systemic fibrin 
clots and thrombotic complications. In each mentioned complication, the positive effects of VitD on the prevention and improvement of viral 
infections have been demonstrated
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cigarette smoke can worsen the severity of COVID-19 
via reducing effective immune response, modulated by 
LL37, and interfering with LL37 in the destruction of 
viruses [65]. Therefore, the use of vitamin D supple-
ments in areas or large cities with air pollution prob-
lems can be helpful in the treatment of COVID-19 
disease.
Figure  3 shows the possible inhibitory mechanism 
by VitD to prevent cytokine and chemokine storms by 
regulating the function of both dendritic cells (DCs) 
and T cells. In DCs, VitD/VDR complex in the nucleus 
down-regulates the expression of CD40, CD80, CD86, 
MHC-II, and up-regulates the expression of IL-3, IL-10 
and CCL22, which results in the induction of T cells [66, 
67]. VitD/VDR complex also can control TLRs signal-
ing through inhibition of miR-155-SOCS1 pathway and 
decrease in the pro-inflammatory cytokine production 
such as TNF-a, IL-6, and IFN-γ [68]. In T-cells, VitD/
VDR can make a complex with RXR that leads to induc-
tion of MKP1 and inhibition of the p38-MAP kinase 
pathway [69]. By inhibiting the MAP kinase pathway, 
p38 is dephosphorylated, which down-regulates the pro-
inflammatory cytokines such as IFN-γ, IL-6, Il-17, IL-23 
and TNF-α. Dephosphorylated p38 can also inhibit the 
maturation of DCs, and the differentiation of Th1 and 
Th17 [69, 70].
Nowadays, VitD deficiency is considered a global 
health problem. Studies have shown a significant asso-
ciation between VitD deficiency and the progression 
of asthma attacks, which may threaten the persistence 
of infection and sepsis [71]. A systematic review and 
meta-analysis examined the efficacy of high-dose VitD 
in pediatric asthma and showed that high-dose VitD may 
prevent asthma exacerbations [72]. Also, Jae Hyoung Im 
and et al. showed vitamin D deficiency with a deficiency 
(< 20 ng/dl) in 76% of the SARS-COV-2 infected patients 
and a severe deficiency (< 10  ng/dl) in 24% [73]. Thus, 
these studies again confirm the potential positive effects 
of VitD supplementation in preventing the severity of 
COVID-19.
Magnesium effect on COVID‑19 through VitD
Some Studies have established a relation between mag-
nesium deficiency, decreased immune cell activity, and 
increased inflammation, which could be significant in 
COVID-19-associated cytokine storm pathology [74]. 
Magnesium, like other trace elements, acts mainly 
through its cofactor or structural role for enzymes. 
Fig. 3 Primary mechanisms by which VitD regulates the function of dendritic cells and T lymphocytes. In DCs, VitD binds to the VitD‑R, which 
is complexed with RXR in the nucleus. VDR/RXR complex decreases expression of MHC‑II, CD40, CD80, and CD86 and enhances the expression 
of CCL22, IL‑10, and IL‑T3, which results in the induction of T‑cells. The VitD stimulates TCR, which induces VDR expression via the alternative 
p38 MAPK pathway. Then, VitD binding to VDR leads to inhibition of proinflammatory cytokine expression, including IFN‑γ, IL‑17, and IL‑21, 
and the development of T‑reg cells. DC dendritic cell, MHC major histocompatibility complex, CCL22 chemokine (C–C motif ) ligand 22, MAPK 
mitogen‑activated protein kinase, T-reg cell T regulatory cell
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Enzymes containing cytochrome P450 are examples of 
these enzymes, which play a role in the metabolism of 
VitD. They are involved in both the activation and inac-
tivation of VitD [49, 75]. The activation is mediated 
by 25-hydroxylase (CYP2R1) and 1α-hydroxylase (i.e., 
CYP27B1), and deactivation is catalyzed by 24-hydrox-
ylase (CYP24A1)[76]. 25-hydroxylation and synthe-
size of 25(OH)D from  VitD3  or  VitD2  is occurred  in 
the liver and followed by 1α-hydroxylation of 25(OH)
D to active 1,25(OH)2D in the kidney. Both 25(OH)D 
and 1,25(OH)2D are metabolized to inactive forms of 
24,25-dihydroxyvitamin D and 1,24,25-trihydroxyvitamin 
D by 24-Hydroxylase, respectively [77]. The dependence 
of these enzymes on magnesium may indicate the role 
of magnesium in maintaining active levels of VitD, and 
in controlling the severity of COVID-19 disease, while it 
requires more clinical and experimental investigations.
The roles of Zinc in the inhibition of acute 
respiratory distress syndrome (ARDS)
Zinc, an important micronutrient especially for enzyme 
activity and zinc fingers, is essential for regulating both 
innate and adaptive immune systems and maintaining 
immune tolerance. It holds the proliferation and matu-
ration of leukocytes and lymphocytes and modulates 
the inflammatory responses. Several studies have shown 
the association between zinc deficiency and the preva-
lence of respiratory infections among the population. 
Rerk suppaphol et al., in a double-blind placebo study of 
zinc supplementation in the treatment of acute respira-
tory tract infections, showed a 45% reduction in the rate 
of acute respiratory infections [78]. Singh et al., in their 
randomized, double-blind, placebo-controlled trial study, 
reported the ameliorative effect of zinc in reducing the 
duration of colds [79]. Some other studies have indi-
cated the antiviral activity of zinc against various viruses 
including influenza [80], rhinovirus, herpes virus, res-
piratory syncytial virus and transmissible gastroenteritis 
virus [81]. Such immunomodulatory and antiviral prop-
erties of zinc, highlights its potential role as a supportive 
agent in the treatment of COVID-19.
Zinc deficiency has a significant effect on bone marrow 
and reduces the production of B lymphocytes and T lym-
phocytes following a decrease in the number of immune 
progenitor cells [82]. Its deficiency also alters the func-
tion and number of blood polymorphonuclear, NK cells, 
and lymphocytes, especially T cells [81]. Zinc is a major 
component of the hormone thymolin, which is involved 
in the development of T cells in the thymus gland [83]. It 
is an essential factor involved in complement activation 
and helps regulate cytokine secretion such as IL-2, IL-6 
and TNF by reducing the formation of pro-inflammatory 
Th9 and Th17 cells [84]. Zinc induces differentiation of 
monocytes to macrophages, increases the phagocytic 
potency of macrophages, and stimulates them to produce 
IL-12 to activate NK and T cells. Zinc also upregulates 
the production of IL-2, IFN-α and IFN-γ and downregu-
lates the production of IL-10 resulting in to promotion of 
antiviral reactions. On the other hand, IFNs can stimu-
late the influx of zinc into the target cells. Decreased 
levels of IL-10 positively affect macrophage function 
and Th1 response [81, 85, 86]. IFNα antiviral activity is 
mediated through JAK1/STAT1 downstream signaling 
and upregulation of antiviral enzymes, including pro-
tein kinase RNA-activated (PKR) and latent ribonucle-
ase (RNaseL) [87]. Such antiviral enzymes are involved 
in the degradation of viral RNA and inhibition of viral 
RNA translation. Both IFN-γ and IL-12 also play a cru-
cial role in the destruction of various pathogens through 
a mechanism including downregulation of ERK1/2 and 
NF-κB pathways [88]. Regulation of ERK1/2 and NF-κB 
pathways has been shown to be necessary for the pro-
tective effect of zinc on the lungs in the infection states. 
Low zinc status upregulates IKK activity and subsequent 
NF-κB signaling resulting in upregulation of target genes 
of TNFα, IL-1β, and ICAM-1 [89, 90]. In their study of 
primary human lung cells, Bao et al. reported that in the 
absence of zinc, treatment with IFN-γ and TNF-α, as well 
as activation of Fas-R signaling, would lead to cell apop-
tosis and impaired pulmonary epithelial barrier function 
[91]. Aydemir et al. also showed that zinc regulates IFN-γ 
expression in human activated T lymphocytes isolated 
from individuals supplemented with 15 mg/day zinc [92]. 
The upregulated IFN-γ in activated human T lympho-
cytes, reduces the release of the cytokine. Such overall 
results indicate that zinc is a vital factor in the protection 
of pulmonary epithelium against acute damage.
Conclusions
COVID-19, as a potentially life-threatening disease, has 
received serious attention from researchers using vari-
ous treatment strategies. Targeted treatments against 
cytokines can prevent the cytokine storm, which brings 
the disease to its final stage. VitD, by affecting NF-κB and 
other pathways, can attenuate various pro-inflamma-
tory cytokines involved in the cytokine storms. Magne-
sium, the critical element in the synthesis and activation 
of VitD, acts as a cofactor for many enzymes involved 
in VitD metabolism. Low zinc status impairs immune 
response and increases susceptibility to viral, bacterial, 
and fungal infections. Excessive inflammatory response 
overproduces pro-inflammatory cytokines and cytokine 
storm, which play a significant role in COVID-19 patho-
genesis. Therefore, it seems that increasing zinc intake 
may be effective in the treatment of COVID-19 by reduc-
ing viral infection and preventing ARDS. So, it can be 
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concluded that concomitant use of a standard drug 
with VitD, magnesium, and zinc may effectively control 
COVID 19 in the early stages and reduce mortality.
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